Enanta Pharmaceuticals, Inc.

Virology-focused Enanta Pharmaceuticals, Inc. took a positive step in its two-mechanism approach to providing a treatment for respiratory syncytial virus (RSV) on 26 September as its RSV L-protein i

Royalty financings were relatively few and far between in the first quarter of 2022, but the number of these financings more than doubled in Q1 of 2023 – from three to seven – and the amount of money

The two biggest biopharmaceutical initial public offerings in the US so far in 2023 occurred during the first week of May, although the largest of the two was a consumer health care spinout from a dru

Gilead Sciences, Inc. has endured some setbacks in bringing its first-in-class capsid inhibitor lenacapavir to the finish line, but with a marketing authorization from the European Medicines Agency o